Canada (Health) v. Glaxosmithkline Biologicals S.A., 2021 FCA 71
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Court of Appeal (Canada) |
| Citation | 2021 FCA 71 |
| Date | 14 April 2021 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
19 practice notes
-
Federal Court Finds Minister Of Health's Refusal Of BELSOMRA CSP Unreasonable, Remits For Redetermination
...decision, along with ViiV Healthcare ULC v. Canada (Health) 2020 FC 756 [JULUCA] and Canada (Health) v. GlaxoSmithKline Biologicals S.A., 2021 FCA 71; rev'g 2020 FC 397 [SHINGRIX], emphasizes the importance of the policy and intent behind the CSP regime, along with Canada's international ob......
-
Federal Court Finds Minister Of Health's Refusal Of BELSOMRA CSP Unreasonable, Remits For Redetermination
...decision, along with ViiV Healthcare ULC v. Canada (Health) 2020 FC 756 [JULUCA] and Canada (Health) v. GlaxoSmithKline Biologicals S.A., 2021 FCA 71; rev'g 2020 FC 397 [SHINGRIX], emphasizes the importance of the policy and intent behind the CSP regime, along with Canada's international ob......
-
Pharma: A Year In Review Through The Lens Of Our Trading Partner To The South
...S.A. v. Canada (Health), 2020 FC 397 (though it should be noted that the FCA allowed an appeal and restored the Minster's decision: 2021 FCA 71; ViiV Healthcare ULC v. Canada (Health), 2020 FC 756; Merck Canada Inc. v. Canada (Health), 2021 FC 2. See Alexion Pharmaceuticals v. Canada (Attor......
-
Pharma: A Year In Review Through The Lens Of Our Trading Partner To The South
...S.A. v. Canada (Health), 2020 FC 397 (though it should be noted that the FCA allowed an appeal and restored the Minster's decision: 2021 FCA 71; ViiV Healthcare ULC v. Canada (Health), 2020 FC 756; Merck Canada Inc. v. Canada (Health), 2021 FC 2. See Alexion Pharmaceuticals v. Canada (Attor......
Request a trial to view additional results
2 cases
-
Catalyst Pharmaceuticals, Inc. v. Canada (Attorney General), 2022 FC 292
...particularly four decisions of the Federal Court of Appeal. Firstly, Médunik cites Canada (Heath) v GlaxoSmithKline Biologicals S.A., 2021 FCA 71, to state that the Federal Court of Appeal held that where there is more than one possible reasonable interpretation of a provision, it is n......
-
Merck Canada Inc. v. Canada (Health),
...Citizenship and Immigration) v Vavilov, 2019 SCC 65 at paras 16–17, 23–25; Canada (Health) v Glaxosmithkline Biologicals SA, 2021 FCA 71 at para 34. [8] A reasonable decision is one that is justified, transparent, and intelligible, reflecting “an internally coherent and......
17 firm's commentaries
-
Federal Court Finds Minister Of Health's Refusal Of BELSOMRA CSP Unreasonable, Remits For Redetermination
...decision, along with ViiV Healthcare ULC v. Canada (Health) 2020 FC 756 [JULUCA] and Canada (Health) v. GlaxoSmithKline Biologicals S.A., 2021 FCA 71; rev'g 2020 FC 397 [SHINGRIX], emphasizes the importance of the policy and intent behind the CSP regime, along with Canada's international ob......
-
Federal Court Finds Minister Of Health's Refusal Of BELSOMRA CSP Unreasonable, Remits For Redetermination
...decision, along with ViiV Healthcare ULC v. Canada (Health) 2020 FC 756 [JULUCA] and Canada (Health) v. GlaxoSmithKline Biologicals S.A., 2021 FCA 71; rev'g 2020 FC 397 [SHINGRIX], emphasizes the importance of the policy and intent behind the CSP regime, along with Canada's international ob......
-
Pharma: A Year In Review Through The Lens Of Our Trading Partner To The South
...S.A. v. Canada (Health), 2020 FC 397 (though it should be noted that the FCA allowed an appeal and restored the Minster's decision: 2021 FCA 71; ViiV Healthcare ULC v. Canada (Health), 2020 FC 756; Merck Canada Inc. v. Canada (Health), 2021 FC 2. See Alexion Pharmaceuticals v. Canada (Attor......
-
Pharma: A Year In Review Through The Lens Of Our Trading Partner To The South
...S.A. v. Canada (Health), 2020 FC 397 (though it should be noted that the FCA allowed an appeal and restored the Minster's decision: 2021 FCA 71; ViiV Healthcare ULC v. Canada (Health), 2020 FC 756; Merck Canada Inc. v. Canada (Health), 2021 FC 2. See Alexion Pharmaceuticals v. Canada (Attor......
Request a trial to view additional results
2 books & journal articles
-
Table of Cases
...rev’g Celgene Inc v Canada (Health), 2012 FC 154 ........................... 252, 258 Canada (Health) v Glaxosmithkline Biologicals SA, 2021 FCA 71, rev’g 2020 FC 397 ....................................................266, 268, 276, 277, 278 Canada (Health) v Pharmascience Inc, 2009 F......
-
Certificates of Supplementary Protection
...Regulatory Impact Analysis Statement ,” SOR/2017-165 (7 September 2017), Canada Gazette II , Vol 151, No 1, 3294 [CSP Regulations]. 5 2021 FCA 71 at para 32, rev’g 2020 FC 397 [ Canada (Health) v Glaxosmithkline ]. 6 RSC 1985, c F-27. after the issuance of the patent. herefore, a pharmaceut......